Characteristics of included cohorts
| Characteristics | Dundee, Scotland | Galway, Ireland | Monza, Italy | Leuven, Belgium | Athens, Greece | Newcastle, England | Vojvodina, Serbia |
|---|---|---|---|---|---|---|---|
| N | 494 | 280 | 250 | 190 | 159 | 126 | 113 |
| Study dates | 2011–2015 | 2008–2015 | 2011–2015 | 2006–2012 | 2010–2015 | 2009–2013 | 2010–2015 |
| Age, mean (SD) | 65.3 (12.9) | 60.5 (14.6) | 65.1 (12.2) | 66.4 (16.0) | 59.3 (16.2) | 59.1 (14.5) | 62 (13.0) |
| Female, n (%) | 300 (60.7) | 188 (67.1) | 147 (58.8) | 97 (51.0) | 101 (64.0) | 75 (59.5) | 80 (70.8) |
| FEV1% predicted, mean (SD) | 71.6 (24.7) | 80.3 (25.9) | 79.2 (27.5) | 69.3 (25.3) | 70.1 (24.9) | 64 (26.9) | 64.8 (26.2) |
| BMI, mean (SD) | 25.9 (5.2) | 27.1 (5.6) | 23.7 (4.4) | 23.9 (4.3) | 24.6 (3.4) | 26.2 (5.1) | 25.1 (4.9) |
| Pseudomonas colonisation, n (%) | 63 (12.8) | 39 (13.9) | 54 (21.6) | 16 (8.4) | 58 (36.5) | 13 (10.3) | 1 (1%) |
| Reiff score, mean (SD) | 4.4 (3.0) | 3.4 (3.0) | 5.5 (2.7) | 4.5 (1.3) | 4.8 (2.5) | 2.8 (1.4) | 4.7 (2.4) |
| MRC dyspnoea score, mean (SD) | 2.3 (1.1) | 2.0 (1.0) | 2.0 (1.3) | 2.3 (1.2) | 2.4 (1.5) | 2.5 (1.1) | 2.5 (1.4) |
| Exacerbations/year, mean (SD) | 2.1 (2.6) | 2.9 (1.3) | 1.9 (2.0) | 1.9 (2.1) | 2.4 (1.5) | 3.4 (1.7) | 1 (1.25) |
| LTOT, n (%) | 8 (1.6) | 9 (3.2) | 35 (14.0) | 10 (5.3) | 26 (16.4) | 0 (0) | 12 (10.6%) |
| Prior hospitalisations, n (%) | 118 (23.9) | 62 (22.1) | 34 (13.6) | 55 (28.9) | 83 (52.2) | 75 (59.5) | 15 (13.3%) |
| BSI, mean (SD) | 7.3 (4.4) | 6.8 (4.5) | 7.3 (4.1) | 7.6 (4.6) | 9.1 (5.4) | 9.7 (4.9) | 6.0 (3.7) |
| FACED, mean (SD) | 2.1 (1.6) | 1.5 (1.5) | 2.3 (1.6) | 1.9 (0.9) | 2.1 (1.8) | 1.6 (1.6) | 2.3 (1.6) |
| End points evaluated | Mortality Hospitalisations Exacerbations Symptoms Quality of life FEV1 decline | Mortality Hospitalisations Exacerbations | Mortality Hospitalisations Exacerbations Symptoms Quality of life FEV1 decline | Mortality Hospitalisations Exacerbations | Mortality Hospitalisations Exacerbations | Mortality Hospitalisations Exacerbations | Mortality Hospitalisations Exacerbations |
| Follow-up time for mortality, years | 4 | 5 | 4 | 5 | 5 | 4 | 5 |
BMI, body mass index; BSI, Bronchiectasis Severity Index; LTOT, long-term oxygen therapy; MRC, Medical Research Council.